a public good project by the
Synthesis
Company
of California

© 2026

Christophe Schmitt | doi.page

0 works0 citations0 h-index

Christophe Schmitt

Roche (Switzerland)(CH)

Publications by Year

Research Areas

Hemophilia Treatment and Research, Platelet Disorders and Treatments, Blood Coagulation and Thrombosis Mechanisms, Coagulation, Bradykinin, Polyphosphates, and Angioedema, Myeloproliferative Neoplasms: Diagnosis and Treatment

Most-Cited Works

→ Emicizumab Prophylaxis in Hemophilia A with Inhibitors(2017)1,046 cited
→ Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors(2018)717 cited
→ Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study(2019)376 cited
→ A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors(2019)367 cited
→ The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes(2017)318 cited
→ Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies(2020)275 cited

→ Disease–Drug–Drug Interaction Involving Tocilizumab and Simvastatin in Patients With Rheumatoid Arthritis(2011)

251 cited

→ Integration of in Vitro Data into Allometric Scaling to Predict Hepatic Metabolic Clearance in Man: Application to 10 Extensively Metabolized Drugs(1997)179 cited

→ The Use of Human Hepatocytes to Select Compounds Based on Their Expected Hepatic Extraction Ratios in Humans(1997)106 cited

→ Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study(2020)94 cited